Daniel M Schmitt insider trades: Actuate Therapeutics (ACTU) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Daniel reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 28, 2026 | ACTU | ↑ Buy | 140,844 | $0.35 | $50K | Direct | Oct 29, 2026 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ACTU insiders
Open-market trades in the last 12 months
About Daniel M Schmitt's insider trades
Daniel M Schmitt is President, CEO and Director at Actuate Therapeutics (ACTU). Since Oct 28, 2026, Daniel has reported 1 open-market purchase worth $50K and no sales on SEC Form 4. In the last 12 months: 1 buy ($50K).
Their filings also include grants and awards (4 filings), shares withheld for taxes (2 filings), option exercises (2 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ACTU insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.